cetuximab,bevacizumab
roche,eli lilly,merck
['beva', 'cetuximab', 'strategic 1', 'bevacizumab']
dr. benoist chibaudel points out in multi-line treatment in unresectable wt kras/nras/braf strategic 1. though there was no difference in quality of life, a treatment strategy starting with folfiri-cetuximab followed by mfolfox6-bevacizumab led to higher response rates. #asco2022 
The Colorectal Cancer Alliance is a national nonprofit fiercely dedicated to ending colorectal cancer within our lifetime. #TomorrowCantWait